Hong Kong Stock Exchange Publishes Consultation Conclusions on Proposals to Enhance Listing Competitiveness
The Stock Exchange of Hong Kong Limited (the Stock Exchange) published its consultation conclusions (the Consultation Conclusions) to its Consultation Paper on the Listing Framework Competitiveness Review (the Consultation Paper). The Listing Rule amendments implementing the Consultation Conclusions took effect immediately upon publication of the Consultation Conclusions on 24 July 2026.
Issuers with active listing applications as at the date of the Consultation Conclusions seeking a listing under Chapter 8 of the Listing Rules may apply to the Stock Exchange to amend their applications so that they may be considered for a listing under Chapter 8A (as an issuer with a WVR structure) and/or under Chapters 18A or 18C (as a Biotech Company or Specialist Technology Company), as applicable, without withdrawing and refiling their applications. Applicants who wish to do so should contact the Stock Exchange, through their sponsors, at the earliest opportunity.
Key Amendments
A summary of the key amendments adopted in the Consultation Conclusions is set out below (modifications and/or clarifications are indicated in bold and underline):
|
Subject |
Old Requirements |
Key Amendments |
|
Weighted voting rights (WVR) |
||
|
Financial eligibility for listing |
Market capitalisation: (A) at least HK$40 billion; or (B) at least HK$10 billion, and revenue for the most recent audited financial year is at least HK$1 billion |
Lower the thresholds to market capitalisation: (A) at least HK$20 billion; or (B) at least HK$6 billion, and revenue for the most recent audited financial year is at least HK$600 million |
|
Voting power |
A class of shares conferring WVR must not entitle the beneficiary to more than 10 times of the voting power of ordinary shares, on any resolution tabled at the issuer’s general meetings (i.e., 10:1 WVR ratio cap) |
Allow a higher weighted voting ratio cap of 20:1 if the applicants have a market capitalisation of at least HK$40 billion at the time of listing |
|
Minimum economic interest at listing |
WVR beneficiaries must beneficially own, collectively, at least 10% of the underlying economic interest in the applicant’s total issued share capital at the time of its initial listing (a lower percentage may be accepted on a case-by-case basis) |
Allow lower minimum underlying economic interest beneficially owned by WVR beneficiaries, only if such underlying economic interest, at the time of the applicant’s initial listing: (a) represents at least 5% of the applicant’s total issued share capital (excluding treasury shares); and (b) has an amount of at least HK$4 billion. This means: (a) Applicants with over HK$40 billion market cap: WVR shareholding may fall below 10%, provided the WVR beneficiaries hold an economic interest of at least HK$4 billion (b) Applicants with HK$80 billion or more market cap: WVR shareholding may be as low as 5% |
|
Innovativeness |
An applicant must demonstrate that it is an “innovative” company for listing with WVR |
Refine the routes that applicants can use to demonstrate that they are innovative companies into, namely, Route A and Route B. An applicant seeking a listing with a WVR structure would be expected to demonstrate that either: Route A (Technology): it adopts technologies that are either novel, in themselves, or essential to the novelty of its core business; or Route B (Business model): its success is attributable to the application, to its core business, of a new business model that may not necessarily be enabled by technology. Where such a business model is enabled by technology, that technology does not have to be novel or essential to the novelty of the issuer’s core business. Innovative Characteristics Route A
Route B
|
|
Applicants that are biotech companies or specialist technology companies are presumed to be innovative if they meet the requirements under Chapter 18A for biotech companies and Chapter 18C for specialist technology companies, respectively |
In addition to applicants that are Specialist Companies (i.e., a biotech company or a specialist technology company) seeking to list under the applicable specialist chapters (under the existing regime), the following groups of applicants that adopt technologies (under Route A) would be presumed to meet the innovative company requirements (even if they do not seek to list under a specialist chapter, i.e., Chapter 18A or 18C): (a) Applicants that: (i) operate in the biotech industry, have been primarily engaged in the R&D of developing at least one core product, and have commercialised that product; (ii) have continued the R&D development of the core product during the 12 months prior to listing; and (iii) have ownership of IP rights relating to the core product (Qualified Biotech Applicants) (b) Applicants that: (i) are primarily engaged in the R&D of, and have commercialised, specialist technology product(s) within an acceptable sector of a specialist technology industry; and (ii) meet the R&D expenditure percentage test designed for a commercial company under Chapter 18C (Qualified Specialist Technology Applicants) |
|
|
External validation |
An applicant must have previously received meaningful third-party investment from at least one sophisticated investor. Biotech companies and specialist technology companies that seek to list with WVR are presumed to satisfy the external validation requirement if:
|
Provide further guidance on the meaning of “sophisticated investors” for the purpose of external validation requirement such that the Stock Exchange:
For Route A applicants, an investment from at least one sophisticated investor would qualify as meaningful third-party investment provided it is more than a token investment. No quantitative minimum investment threshold would be imposed. For Route B applicants, the Stock Exchange will provide more certainty on what constitutes “meaningful third-party investment”:
|
|
Issuers Listed Overseas |
||
|
Qualification requirements for secondary listing |
An overseas issuer seeking a secondary listing on the Stock Exchange with a WVR structure must have a track record of good regulatory compliance of at least two full financial years on a Qualifying Exchange (i.e., The New York Stock Exchange LLC, Nasdaq Stock Market, or the Main Market of the London Stock Exchange plc) and must have either:
|
Lower the financial eligibility thresholds for a secondary listing of an overseas issuer with a WVR structure to align them with those proposed for WVR issuers with a primary listing, such that:
|
|
An overseas issuer seeking a secondary listing without a WVR structure must satisfy either Criteria A or Criteria B: Criteria A (1) A track record of good regulatory compliance of at least five full financial years on a Qualifying Exchange or (only for issuers without a centre of gravity in Greater China) any Recognised Stock Exchange; and (2) a market capitalisation of at least HK$3 billion at the time of listing. Criteria B (3) A track record of good regulatory compliance of at least two full financial years on a Qualifying Exchange; and (4) a market capitalisation of at least HK$10 billion at the time of listing. |
Lower the market capitalisation threshold under Criteria B from HK$10 billion to HK$6 billion The market capitalisation threshold under Criteria A would be retained |
|
|
Initial Listing Requirements and Listing Arrangements |
||
|
Ownership continuity and control |
An applicant must have been operating as an integrated unit under the same shareholder that is able to exert substantial influence on the management in the relevant period |
Codify existing guidance into a Listing Rule requirement stating that an applicant will be considered to have satisfied the ownership continuity requirement if it can demonstrate, to the Stock Exchange’s satisfaction, that there was no material change in influence on management during the relevant period despite a change in controlling shareholder over that period to address any packaging concerns. Updated Chapter 1.1C of the Guide for New Listing Applicants to emphasise:
|
|
Financial reporting standards |
An applicant listed / to be listed in the US and seeking a dual primary or secondary listing in Hong Kong may apply for a waiver to adopt Generally Accepted Accounting Principles in the United States of America (US GAAP) |
Expand the permitted use of US GAAP to: (i) subsidiary companies of a US-listed parent seeking to list on the Stock Exchange; and (ii) companies with substantial business operation(s) in the US, subject to the following conditions:
|
|
Requirement that US GAAP reporters must revert to preparing financial statements using HKFRS or IFRS if it delists from the US |
Remove this requirement |
|
|
Requirement that where relevant financial statements are not audited or reviewed by auditors, the reconciliation statement of US GAAP reporters must be reviewed by auditors |
Remove this requirement |
|
|
Commercialised biotech and specialist technology applicants |
If Biotech Companies and Specialist Technology Companies (as defined in the Listing Rules) are able to satisfy any financial eligibility test under Chapter 8 of the Listing Rules, they must list under the ordinary listing route (Chapter 8) rather than under the specialist routes for Biotech Companies and Specialist Technology Companies under Chapter 18A and Chapter 18C, respectively |
Allow Biotech Companies and Specialist Technology Companies to seek a listing under the applicable specialist chapters even if they satisfy one or more of the Rule 8.05 eligibility tests (Eligible Specialist Companies)
|
|
For an Eligible Specialist Company seeking a listing as a commercialised Biotech Company under Chapter 18A:
|
||
|
For an Eligible Specialist Company seeking a listing as a commercialised Specialist Technology Company under Chapter 18C:
|
||
|
Double-dipping:
|
||
|
Confidential filing |
Confidential filing is only available to eligible secondary listing applicants, Biotech Companies, and Specialist Technology Companies, or subject to case-by-case waivers for other applicants |
Expand the confidential filing option to all new applicants (i.e., the non-public filing option), so a new applicant may choose not to publish an application proof (AP) at the time it submits its listing application, in which case it only needs to publish an Overall Coordinator (OC) announcement on the same date as it publishes its post hearing information pack (PHIP). An applicant that has opted for non-public filing at the time of its listing application may subsequently elect to publish its draft listing document before the publication of the PHIP, subject to the following conditions:
A new applicant may still opt for publication of its AP (i.e., public filing option) upon the submission of its listing application. In such circumstances, the OC announcement must be published on the same date as its listing application, the existing requirements on the content and the prescribed timing for publishing, and an AP would continue to apply. |
|
Return mechanism if application materials are not substantially complete |
An application that is not substantially complete may be returned, upon which the sponsor’s identity will be displayed on the Stock Exchange’s website |
In addition to the identities of the sponsors, the names and roles of other professional parties involved in the proposed listing will also be displayed on the designated webpage of the Stock Exchange, including:
The reasons for return will also be displayed. |
|
The applicant whose application has been returned can only submit a new listing application no less than eight weeks after the date of the Listing Division’s decision to return the listing application |
Amend the starting point of the eight-week moratorium from the date of the Listing Division’s decision to either: (a) the date on which the time period for invoking any applicable review procedures has lapsed; or (b) where the applicant invokes such procedures, the date on which all applicable review procedures in respect of that decision have been completed |
|
Change of Listing Status From Secondary Listing to Primary Listing
The Stock Exchange has updated HKEX-GL-112-22 to present in a more accessible manner the typical steps and key requirements for conversion from secondary listing to dual-primary listing or primary listing. A change of listing status may occur via one of four routes: (i) migration of the majority of trading in the issuer’s listed shares to the Stock Exchange’s markets (Migration); (ii) a voluntary primary conversion (Primary Conversion); (iii) an involuntary overseas de-listing (Overseas De-listing (involuntary)); or (iv) a voluntary overseas de-listing (Overseas De-listing (voluntary), together with Overseas De-listing (involuntary)).
The trigger and effect of each route differ materially. Migration and Primary Conversion both result in the issuer being regarded as having a dual-primary listing, whereas both forms of Overseas De-listing result in the issuer being regarded as having a primary listing. Migration is the only route that occurs automatically rather than by the issuer’s election and is the only route that carries a 12-month grace period (the Migration Grace Period) for compliance with the Listing Rules.
By contrast, an issuer undergoing a Primary Conversion or an Overseas De-listing (whether voluntary or involuntary) is expected to comply with all applicable Listing Rules immediately upon the relevant effective date, and a grace period will not normally be granted. Once the change of listing status takes effect, all exemptions and waivers available to the issuer on the basis of, or conditional upon, its secondary listing status will cease to apply, save for certain transitional arrangements (summarised in the table below).
The table below summarises the key differences between the four routes under Guidance Letter HKEX-GL-112-22, based on the appendix to that guidance letter, together with additional key points to note:
|
Features |
Migration |
Primary Conversion |
Overseas |
Overseas |
|
General effect of a change of listing status |
||||
|
Resulting listing status |
Dual-primary listing |
Primary listing |
||
|
Change of listing status timing |
Upon expiry of the 12-month Migration Grace Period, which runs from the date of the Stock Exchange’s migration exchange notice |
Upon the effective date specified of the Primary Conversion |
Upon the effective date of the overseas de-listing |
|
|
Effect on exemptions / waivers tied to secondary listing status |
Disapply upon expiry of the Migration Grace Period |
Disapply upon the effective date of the Primary Conversion |
Disapply upon the effective date of the overseas de-listing |
|
|
Stock marker |
The “S” marker is disapplied only once the issuer is in full compliance with all applicable Listing Rules — it may continue beyond expiry of the Migration Grace Period if the issuer is not yet compliant |
“S” is disapplied from the effective date of Primary Conversion A “TP” (transitional) marker may instead be applied where the Stock Exchange grants an exceptional grace period |
“S” is disapplied from the effective date of overseas de-listing A “TP” marker may be applied where an exceptional grace period is granted |
|
|
Continued use of an alternative overseas financial reporting standard |
||||
|
Issuer listed in the US adopting US GAAP |
Permitted to continue to adopt US GAAP upon change of listing status |
|||
|
Issuer incorporated in EU adopting EU-IFRS |
Permitted to continue to adopt EU-IFRS upon change of listing status |
|||
|
Issuers adopting other alternative overseas standards |
Permitted to continue if the issuer maintains a primary listing in the jurisdiction of that standard |
Permitted to continue if the issuer maintains a primary listing in the jurisdiction of that standard |
Issuer must revert to HKFRS or IFRS for financial statements falling due after the first anniversary of the de-listing |
|
|
Notifiable/Connected Transactions and WVR/VIE Structures |
||||
|
Three-year exemption for continuing connected and/or notifiable transactions entered into before a change of listing status takes effect and will continue thereafter |
Available for continuing transactions entered into before the start of the Migration Grace Period and will continue after change of listing status |
Not available — full compliance with Chapters 14/14A is required for continuing transactions conducted after the Primary Conversion |
Available for continuing transactions entered into before submission of the overseas de-listing issuer notification and will continue after change of listing status |
Not available — full compliance with Chapters 14/14A is required for continuing transactions conducted after the overseas de-listing |
|
Retention of non-compliant WVR/VIE structures |
Grandfathered Greater China Issuers and Non-Greater China Issuers may retain non-compliant WVR and/or VIE structures following change of listing status |
|||
Conclusion
The new requirements adopted in the Consultation Conclusions are of significant relevance to companies considering a listing on the Stock Exchange, particularly those in the technology and biotech sectors. In particular, listing applicants should note the following:
- The reduction in the market capitalisation thresholds for WVR companies will enable more mid-sized technology and innovative companies to list on the Stock Exchange with a WVR structure
- The refinement of the innovative company requirements into two routes — Route A (Technology) and Route B (Business Model) — provides a clearer listing route for different types of innovative companies
- Biotech companies and specialist technology companies that already meet the financial eligibility tests will have the option to list under the applicable specialist chapters, providing flexibility to listing applicants
- The expansion of non-public filing to all new applicants will help protect sensitive information such as applicants’ operational strategies and proprietary technologies during the listing application process
We recommend that applicants considering a listing on the Stock Exchange review the new requirements carefully and assess the opportunities presented by these reforms. In particular, issuers with active listing applications should consider whether to apply to amend their applications to take advantage of the new listing routes now available.